Rapid Therapeutic Science Laboratories, Inc. RTSL
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 101.74% | 99.39% | 37.42% | -22.43% | -- |
| Total Depreciation and Amortization | -63.36% | 6.67% | -30.43% | 48.47% | -- |
| Total Amortization of Deferred Charges | -79.74% | -34.28% | 53.60% | 360.71% | -- |
| Total Other Non-Cash Items | 17.47% | -247.71% | -119.73% | -123.87% | -- |
| Change in Net Operating Assets | -125.85% | -47.73% | 126.76% | 571.76% | -- |
| Cash from Operations | 70.14% | 79.28% | 47.87% | 43.64% | -- |
| Capital Expenditure | 151.94% | 98.70% | 86.60% | -304.73% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 151.94% | 98.70% | 86.60% | -304.73% | -- |
| Total Debt Issued | -85.12% | -68.02% | -32.65% | -52.01% | -- |
| Total Debt Repaid | -628.93% | -- | 4.03% | 67.17% | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -94.51% | -81.00% | -54.51% | -69.77% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -271.07% | 89.87% | 37.21% | -240.69% | -- |